Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-02-06
1998-06-02
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514255, 514256, 514269, 514272, 514274, 514340, 514345, 514348, 514349, 514351, 514352, 514357, 544238, 544405, 544297, 544298, 544310, 544316, 544317, 544319, 544321, 544322, 544324, 544327, 544331, 544333, 5462721, A61K 31525, A61K 31505, C07D40500, C07D40900
Patent
active
057600384
ABSTRACT:
Compounds of the formula ##STR1## in which the symbols are as defined herein, inhibit the activity of endothelin.
REFERENCES:
patent: 2888455 (1959-05-01), Kano et al.
patent: 4415496 (1983-11-01), Harris et al.
patent: 5236928 (1993-08-01), Chakravarty et al.
patent: 5270313 (1993-12-01), Burri et al.
patent: 5292740 (1994-03-01), Burri et al.
patent: 5378715 (1995-01-01), Stein et al.
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5571821 (1996-11-01), Chan et al.
patent: 5591761 (1997-01-01), Chan et al.
patent: 5594021 (1997-01-01), Chan et al.
patent: 5612359 (1997-03-01), Murugesan
S. Norio et l., Chemical Abstracts, vol. 70, No. 19, (1969), 87639g.
T. Saito, Chemical Abstracts, vol. 73, No. 23 (1970), 120511w.
Derwent Abstract No. 88-289069/41 Feb. 27, 1987.
Derwent Abstract No. 88-195835/28 Nov. 26, 1986.
Derwent Abstract No. 88-061295/09 Jul. 9, 1986.
Derwent Abstract No. 87-152485/22 Oct. 11, 1985.
Derwent Abstract No. 62299 E/30 Dec. 11, 1980.
Derwent Abstract No. 40927 D/23 Sep. 11. 1979.
Derwent Abstract No. 91-254550/35 Feb. 19, 1990.
Derwent Abstract No. 86-246709/38 Nov. 27, 1985.
Derwent Abstract No. 35012 K/15 Sep. 24, 1981.
Allen et al., "Preparation . . . antagonists", CA116(11):106284Z, p. 778, 1992.
R.D. Desai et al., Chemical Abstracts, vol. 71, No. 11, (1969) 49825c.
R.D. Desai et al., Chemical Abstracts, vol. 71, No. 3, (1969) 12872q.
P. G. Ferrini et al., Angew. Chem. Internat. Edit., vol. 2. No. 2 (1963) p. 99.
A. M. van Leusen, et al., "Synthesis . . . Compounds" J. Org. Chem., vol. 41, 4, (1976), pp. 69-71.
W. J. Hammar et al., J. Heterocyclic Chem., vol. 18, (1981) pp. 885-888.
A. M. van Leusen et al., Tetrahedron Letters, No. 23, (1972), pp. 2369-237.
Chan et al., "Identification of a New Class of ET.sub.A Selective Endothelin Antagonists by Pharmacophore Directed Screening", Biochemical and Biophysical Research Communications, vol. 201, No. 1, May 30, 1994, pp. 228-234.
Stein et al., "The Discovery of Sulfonamide Endotheiin Antagonists and the Development of the Orally Active ET.sub.A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide", J. Med. Chem., vol. 37, No. 3, Feb. 4, 1994, pp. 329-331.
Doherty, J. Med. Chem., 35(9), 1493-1508 (May 1992).
CA 65: 2241d (1966).
CA 92:41908v (1980).
Wang et al., "Nitrile . . . sinomin," CA 108:94444w, p. 651 (1988).
Khanna, "Oral . . . formulation," CA 115:35728p, p. 415 (1991).
Stein et al., "The Discovery . . . 1-naphthalenesulfonamide," CA 120:18233n, pp. 21-22 (1994).
Vree et al., "Renal excretion . . . function," CA 97:84685r, p. 23 (1982).
Oie, "Pharmacokinetics . . . dosing," CA102:197512x, p. 18 (1985).
Murugesan et al., "N-(heteroaryl) . . . antagonists," CA 120:270370c, p. 1067 (1994).
Barrish Joel C.
Murugesan Natesan
Stein Philip D.
Babajko Suzanne E.
Berch Mark L.
Bristol--Myers Squibb Company
Kifle Bruck
LandOfFree
Substituted biphenyl sulfonamide endothelin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted biphenyl sulfonamide endothelin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted biphenyl sulfonamide endothelin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1460054